egfr inhibitor eras-801
egfr inhibitor eras-801: sourced relationships with 1 company · 3 clinical trials tracked.
egfr inhibitor eras-801 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could egfr inhibitor eras-801 → ERAS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Erasca, Inc. (ERAS) Metastatic Solid Tumors | Phase 1/Phase 2 |
Clinical Trial Registry Records (3)
A Phase Ib Open Label Clinical Trial to Evaluate the Safety and Efficacy of ERAS-801 in Surgically Accessible Recurrent Glioblastoma Patients With EGFR Amplification or Mutation (ERAS801-SARG)
Primary endpoint: Incidence of adverse events
Phase Ib Trial of ABBV-637 or ABBV-155 in Combination With ERAS-801 for Glioblastoma With Amplification of the Epidermal Growth Factor Receptor
Primary endpoint: Dose limiting toxicity (DLT)
A Phase 1 Study to Evaluate the CNS-Penetrant EGFR/ERBB1 Inhibitor ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
Primary endpoint: Dose Limiting Toxicities (DLT)
Frequently asked questions
Which companies have sourced relationships with egfr inhibitor eras-801?
egfr inhibitor eras-801 has dated SEC/FDA relationship records for Erasca, Inc..
How many clinical trials involve egfr inhibitor eras-801?
BioSniper tracks 3 clinical trials involving egfr inhibitor eras-801.